121
Participants
Start Date
March 3, 2015
Primary Completion Date
March 4, 2019
Study Completion Date
March 4, 2019
AMG 157
AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
Cat Immunotherapy
A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
Cat Immunotherapy Placebo
Placebo for allergen-specific immunotherapy administered subcutaneously
AMG 157 Placebo
Placebo for AMG 157 administered intravenously
Johns Hopkins Asthma & Allergy Center, Baltimore
University of North Carolina, Chapel Hill, Chapel Hill
University Wisconsin, Madison, Madison
Northwestern University, Chicago
University of Chicago, Chicago
Vital Prospects Clinical Research Institute, P.C., Tulsa
National Jewish Health, Denver
University of California, Los Angeles, Los Angeles
ASTHMA Inc. Clinical Research Center, Seattle
Immune Tolerance Network (ITN)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH